1. The use of an effective amount of a composition that increases the expression of miRNA-31 or reduces the expression of RhoA, to obtain a medicine for: (i) increasing the expression of interleukin-2 (IL-2) in a subject in need thereof, where the subject in need thereof is a subject suffering from systemic lupus erythematosus； (ii) increasing the expression of interleukin-2 (IL-2) in T cells in a subject suffering from systemic lupus erythematosus； (iii) treating systemic lupus erythematosus； (iv) reducing the expression of RhoA in a subject needing it where with The object is in need of it, is a subject suffering from systemic lupus erythematosus； or (v) a decrease in RhoA expression in T cells of a subject suffering from systemic lupus erythematosus. 2. The use according to claim 1, characterized in that the subject suffering from systemic lupus erythematosus experiences symptoms of exacerbation of diseases. The use according to claim 1, characterized in that the subject suffering from systemic lupus erythematosus does not experience symptoms of exacerbation of the disease. The use according to claim 2, characterized in that the subject's symptoms include lupus nephritis. The use according to claim 3, characterized in that the subject's symptoms include lupus nephritis. The use according to claim 1, characterized in that the T cells are in vitro activated T cells. The use according to any one of claims 1 to 6, characterized in that the composition comprises a nucleic acid containing a nucleotide sequence that increases the expression of miRNA-31.8. The use according to claim 7, characterized in that the composition contains miRNA-31.9. The use according to claim 7, characterized in that the composition contains a small interfering nucleic acid (mi�1. Применение эффективного количества композиции, которая увеличивает экспрессию микроРНК-31 или уменьшает экспрессию RhoA, для получения лекарственного средства для:(i) повышения экспрессии интерлейкина-2 (IL-2) у субъ
